New Cardiac Troponin Submissions Will Have To Meet Revised Standards
This article was originally published in The Gray Sheet
Executive Summary
Companies developing new or modified cardiac troponin assays should be sure to talk to FDA before pursuing pre-market studies because standards have changed, the agency says in a letter sent to manufacturers last week.